Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
MLN0002
National Institutes of Health
Create Alert
Related topics
Related topics
2 relations
LDP 02
Broader (1)
vedolizumab
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Vedolizumab safety in pregnancy and newborn outcomes
M. Julsgaard
,
J. Kjeldsen
,
D. Baumgart
Gut
2017
Corpus ID: 206966015
We read with interest the study by Colombel et al 1 on vedolizumab (VDZ) safety in Crohn's disease (CD) and ulcerative colitis…
Expand
Review
2015
Review
2015
Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab
N. Krupka
,
D. Baumgart
Drug design, development and therapy
2015
Corpus ID: 1198094
Crohn’s disease and ulcerative colitis are two chronic inflammatory bowel conditions. Current approved biologic therapies are…
Expand
Review
2015
Review
2015
Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
M. Essat
,
P. Tappenden
,
+5 authors
S. Hoque
PharmacoEconomics
2015
Corpus ID: 3062745
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited…
Expand
Highly Cited
2012
Highly Cited
2012
Exclusive antagonism of the &agr;4&bgr;7 integrin by vedolizumab confirms the gut‐selectivity of this pathway in primates
E. Fedyk
,
T. Wyant
,
+4 authors
V. Kadambi
Inflammatory bowel diseases
2012
Corpus ID: 12242501
Background: Biological therapies that antagonize specific molecules have demonstrated efficacy in inflammatory bowel diseases…
Expand
Review
2011
Review
2011
Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis
S. Thomas
,
D. Baumgart
Inflammopharmacology
2011
Corpus ID: 11663330
Crohn’s disease and ulcerative colitis are two chronic inflammatory bowel diseases. Current biologic therapies are limited to…
Expand
2010
2010
Veto on vedolizumab (MLN0002) for Crohn's disease.
D. Baumgart
Inflammatory bowel diseases
2010
Corpus ID: 35402548
2009
2009
P164 - Clinical pharmacology of vedolizumab (MLN0002) in patients with active ulcerative colitis
C. Scholz
,
T. Wyant
,
+6 authors
L. Moltke
2009
Corpus ID: 74433339
2009
2009
P130 - Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to α4β7 integrin
A. Parikh
,
E. Fedyk
,
+5 authors
I. Fox
2009
Corpus ID: 57829234
Highly Cited
2008
Highly Cited
2008
Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.
B. Feagan
,
G. Greenberg
,
+10 authors
A. Parikh
Clinical gastroenterology and hepatology : the…
2008
Corpus ID: 11473493
BACKGROUND & AIMS Selective blockade of lymphocyte-vascular endothelium interactions in the gastrointestinal tract is a promising…
Expand
2008
2008
Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to the alpha4beta7 integrin: P-0025.
A. Parikh
,
E. Fedyk
,
+5 authors
I. Fox
2008
Corpus ID: 75484690
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE